ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 183

Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model

Goh Murayama1, Asako Chiba2, Hitomi Toda2, Ken Yamaji1, Naoto Tamura3 and Sachiko Miyake4, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, 3Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Immunology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Dermatopathology, drug treatment, mouse model and psoriasis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is a chronic inflammatory disease of the skin and is often accompanied by arthritis. The underlying pathogenesis of psoriasis is still unclear, but T-helper 1 (Th1) and Th17 cells are thought to play important roles. Mucosal-associated invariant T (MAIT) cells are innate lymphocytes that are restricted by MHC-related molecule-1 (MR1), express a semi-invariant TCRa chain: Va7.2-Ja33 in humans and Va19-Ja33 in mice. Previously, we have shown that MAIT cells inhibited the progression of autoimmune encephalomyelitis (EAE), and the inhibition of EAE was accompanied by reduced autoreactive Th1 and Th17 responses. Therefore, we sought to investigate whether MAIT cells have a suppressive role in an animal model of psoriasis by using MR1-/- mice lacking MAIT cells.

Methods: A murine imiquimod (IMQ)-induced model of psoriasis (J Immunol. 2009; 182: 5836-45) was induced in MR1-/- and MR1+/+C57BL/6J mice at 8 to 10 weeks of age. Mice were topically treated with 62.5mg of 5% IMQ cream (Mochida Pharmaceutical) on the shaved back for 5 consecutive days. Mice were injected with 500ml of phosphate-buffered saline on day 1 and 3. The severity of skin inflammation was monitored every day, and scored by usning linical Psoriasis Area and Severity Index (PASI) score. Erythema, scaling, and thickening of the back skin were scored on the scale from 0 to 4. (J Immunol. 2009; 182: 5836-45). Skin samples were stained with haematoxylin-eosin, and the severity were graded on a scale of 1 to 3 for acanthosis; 1 to 2 for hyperkeratosis, interface liquefaction, inflammation, dermal cellularity, presence of dilated vessels with hemorrhage; 0 to 1 for ulcer or erosion. Differences between groups were assesed using the Mann-Whitney U test, and the significance level was set at p < 0.05.

Results: Both MR1-/- and MR1+/+C57BL/6J mice equally developed erythema. MR1-/-C57BL/6J mice displayed significantly severe scales and thickness of the back skin than MR1+/+ mice. The histopathological analysis revealed there was a significant worsening of dermatitis and the higher dermatitis score in MR1-/- mice compared to control MR1+/+C57BL/6J mice.

Conclusion: The present study indicated that MAIT cells play a suppressive role for the development of psoriasis. In humans, MAIT cells have recently been found in normal and psoriatic skin. Although further verification for mechanisms of the function of MAIT cells for pathogenesis of psoriasis, regulation of MAIT cell functions may become a novel therapeutic strategy for psoriasis.


Disclosure: G. Murayama, None; A. Chiba, None; H. Toda, None; K. Yamaji, None; N. Tamura, None; S. Miyake, ASUBIO PHARMA CO., LTD, 2,TAIHO PHARMACEUTICAL CO., LTD., 5.

To cite this abstract in AMA style:

Murayama G, Chiba A, Toda H, Yamaji K, Tamura N, Miyake S. Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/protective-role-of-mucosal-associated-invariant-t-mait-cells-in-an-imiquimod-induced-psoriasis-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/protective-role-of-mucosal-associated-invariant-t-mait-cells-in-an-imiquimod-induced-psoriasis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology